Biological response modifiers used in cancer biotherapy.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Anticancer Research

• Publication date

  2012-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 22641656
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.

  2014cited by this paper
• Combination of glucan, resveratrol and vitamin C demonstrates strong anti-tumor potential.

  2012cited by this paper
• Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: potential role in prevention and therapy of cancer.

  2012cited by this paper
• Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays.

  2012cited by this paper
• Polysaccharide-K (PSK) in cancer--old story, new possibilities?

  2012cited by this paper
• Efficacy and feasibility of induction chemotherapy and radiotherapy plus cetuximab in head and neck cancer.

  2012cited by this paper
• Lenograstim

  2011cited by this paper
• Phase I study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.

  2011cited by this paper
• Thirty-five years of intravesical bacillus Calmette-Guérin for bladder cancer: where now?

  2011cited by this paper
• Cancer immunotherapy.

  2011cited by this paper
• Lipopolysaccharide IP-PA1 from Pantoea agglomerans prevents suppression of macrophage function in stress-induced diseases.

  2011cited by this paper
• Adjuvant Trastuzumab in HER 2-Positive Breast Cancer

  2011cited by this paper
• Characterization of Interferon-γ–Treated Melanoma Tumor Cells for Use in Dendritic Cell-Based Immunotherapy

  2011cited by this paper
• Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.

  2011cited by this paper
• Sipuleucel-T for prostate cancer: the immunotherapy era has commenced

  2011cited by this paper
• Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer.

  2011cited by this paper
• Adjuvant trastuzumab in HER2-positive breast cancer.

  2011cited by this paper
• Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine

  2011cited by this paper
• Immune modulating effects of β-glucan

  2010cited by this paper
• A review of immunomodulators with reference to Canova®

  2009cited by this paper
• Differences in depressive thoughts between major depressive disorder, IFN-alpha-induced depression, and depressive disorders among cancer patients.

  2008cited by this paper
• Current and future anti-TNF therapy for inflammatory bowel disease

  2007cited by this paper
• Combination immunotherapy with prostatic acid phosphatase pulsed antigen‐presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy

  2006cited by this paper
• Cancer vaccines

  2005cited by this paper
• Cytokine Therapy

  2005cited by this paper
• Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.

  2005cited by this paper
• The impact of new biologicals in the treatment of rheumatoid arthritis.

  2004cited by this paper
• Application of recombinant antibodies in cancer patients.

  2003cited by this paper
• Spontaneous regression of neoplasms: new possibilities for immunotherapy

  2002cited by this paper
• From Bench to Bedside: Development of Rituximab (Rituxan®), A Monoclonal Antibody for the Therapy of Non-Hodgkin's Lymphoma

  2002cited by this paper
• Significance of tumor-associated antigens in the diagnosis and therapy of cancer: an overview.

  2002cited by this paper
• Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy.

  2001cited by this paper
• Treatment of carcinoma in situ of the urinary bladder with bropirimine.

  1997cited by this paper
• Effects of glycosylated and non-glycosylated G-CSFs, alone and in combination with other cytokines, on the growth of human progenitor cells.

  1996cited by this paper
• Antibiotics as biological response modifiers.

  1990cited by this paper
• Basic methods in molecular biology

  1986cited by this paper

• Advances in cancer immunotherapy: Strategies and innovations strategies for adoptive immunotherapy of cancer

  2025influential citation
• Recent advances of nanocrystals in cancer theranostics

  2023cites this paper
• The intrapleural administration with thymic peptides in malignant pleural effusion: A clusteredsystematicreview and meta-analysis.

  2022cites this paper
• Mushrooms as a Resource for Mibyou-Care Functional Food; The Role of Basidiomycetes-X (Shirayukidake) and Its Major Components

  2022cites this paper
• The Potential for Phospholipids in the Treatment of Airway Inflammation: An Unexplored Solution.

  2021cites this paper
• Pharmacological Effects of Guava (Psidium guajava L.) Seed Polysaccharides: GSF3 Inhibits PC-3 Prostate Cancer Cell Growth through Immunotherapy In Vitro

  2021cites this paper
• Emerging nanotaxanes for cancer therapy.

  2021cites this paper
• Plants Used for the Traditional Management of Cancer in the Eastern Cape Province of South Africa: A Review of Ethnobotanical Surveys, Ethnopharmacological Studies and Active Phytochemicals

  2021cites this paper
• Structural Elucidation of Immunomodulators, Acetylated Heteroglycan and Galactosamine, Isolated from Aloe arborescens Leaves

  2020cites this paper
• Intracellular Signaling

  2020cites this paper
• A Review of IMMUNEPOTENT CRP, A Modifier of Biological Response: Efficacy and Current Practice

  2019cites this paper
• Chapter 2 Biological Response Modifier in Cancer Immunotherapy

  2018cites this paper
• Assessment of Immunomodulatory Activities and in vitro Toxicity of New Quinolone 7-ethyl 9-ethyl-6-oxo-6,9-dihydro[1,2,5]selenadiazolo[3,4-h]quinoline-7-carboxylate

  2017cites this paper
• Evidence-Based Review of BioBran/MGN-3 Arabinoxylan Compound as a Complementary Therapy for Conventional Cancer Treatment

  2017cites this paper
• Biological Response Modifier in Cancer Immunotherapy.

  2016cites this paper
• A Biodegradable Microparticle Vaccine Platform using Femtomole Peptide Antigen Doses to Elicit T-cell Immunity against Chlamydia abortus

  2016cites this paper
• Anticancer activity of tuftsin-derived T peptide in postoperative residual tumors

  2014cites this paper
• Cancer Biotherapy: The Best is Yet to Come

  2013cites this paper
• Biologic response modifiers

  2013cites this paper
• Cancer therapeutic drug guide

  year unknowncites this paper